KYOWA KIRIN SERVICES LTD
Get an alert when KYOWA KIRIN SERVICES LTD files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2026-09-30 (in 4mo)
Last filed for 2024-12-31
Confirmation statement due
2027-03-13 (in 10mo)
Last made up 2026-02-27
Watchouts
None on the register
Cash
£358K
+108.1% vs 2023
Net assets
£339M
+48.6% vs 2023
Employees
132
-18.5% vs 2023
Profit before tax
£142M
+117.5% vs 2023
Name history
Renamed 3 times since incorporation
- KYOWA KIRIN SERVICES LTD 2017-12-29 → present
- ARCHIMEDES DEVELOPMENT LIMITED 2005-03-04 → 2017-12-29
- WEST PHARMACEUTICAL SERVICES DRUG DELIVERY & CLINICAL RESEARCH CENTRE LIMITED 1999-03-04 → 2005-03-04
- DANBIOSYST UK LIMITED 1989-03-13 → 1999-03-04
Net assets
2-year trend · vs Industrials median
Accounts
2-year trend · latest reflected 2024-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Turnover | £300,610,000 | £258,656,000 | |
| Operating profit | £28,062,000 | £125,916,000 | |
| Profit before tax | £65,529,000 | £142,494,000 | |
| Net profit | £55,089,000 | £110,782,000 | |
| Cash | £172,000 | £358,000 | |
| Total assets less current liabilities | £228,058,000 | £340,197,000 | |
| Net assets | £228,058,000 | £338,840,000 | |
| Equity | £228,058,000 | £338,840,000 | |
| Average employees | 162 | 132 | |
| Wages | £26,551,000 | £27,026,000 |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating margin | 9.3% | 48.7% | |
| Net margin | 18.3% | 42.8% | |
| Return on capital employed | 12.3% | 37.0% | |
| Current ratio | 1.51x | 1.92x | |
| Interest cover | 11.59x | 36.56x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- FRS 101 Reduced Disclosure Framework
- Reporting scope
- Standalone (parent only)
- Auditor
- KPMG LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“Consequently, the directors are confident that the Company will have sufficient funds to continue to meet its liabilities as they fall due for at least 12 months from the date of approval of the financial statements and therefore have prepared the financial statements on a going concern basis.”
Group structure
- KYOWA KIRIN SERVICES LTD · parent
- Kyowa Kirin Ltd 100%
- Kyowa Kirin Farmaceutica SLU 100%
- Kyowa Kirin GmbH 100%
- Kyowa Kirin S.r.l. 100%
- Kyowa Kirin AB 100%
- Kyowa Kirin Austria GmbH 100%
- Kyowa Kirin Pharma s.r.o 100%
- Kyowa Kirin Ireland Ltd 100%
- Kyowa Kirin S.a.r.l 100%
- Kyowa Kirin Farmacêutica, Unipessoal Lda 100%
- Kyowa Kirin Pharma FZ-LLC 100%
- Kyowa Kirin Holdings BV 100%
- Kyowa Kirin Pharma SAS* 100%
- Kyowa Kirin Pharma BV* 100%
- Kyowa Kirin Pharma S.r.I' 100%
Significant events
- “The decrease in sales is mainly attributed to the full-year impact of the disposal of the Established Medicines portfolio, which the Company ceased selling from 1 July 2023.”
- “During the year, the Company established a Dutch branch for the purpose of setting up a central warehousing and distribution centre for the KKI Group. The project represented a pivotal shift in KKI Group's central distribution strategy, aimed at optimising supply chain and enhancing operational efficiency.”
- “The Company and the wider KKI Group made further progress in respect of its digital transformation agenda during the year.”
- “Third party revenues for 2024 are lower compared to 2023, primarily due to a one-time transaction related to the disposal of certain product rights.”
- “As part of the rationalisation of the Rare Diseases division, the company recognised restructuring costs of £1.1 million for the year (2023: £2.8 million).”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
4 active · 34 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| MCS FORMATIONS LIMITED | Corporate Secretary | 2015-02-17 | — | — |
| ARISTIDOU, Antrinkos Andrew | Director | 2020-09-28 | Jun 1968 | British |
| DEHAENE-PUYPE, Julie Helene Madeleine | Director | 2025-11-03 | Apr 1973 | French |
| REISINGER, Roswitha, Dr | Director | 2020-04-22 | May 1970 | Austrian |
Show 34 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| DAVIS, Stanley Stewart, Professor | Secretary | — | 1996-03-18 |
| FOX, Christine Joy | Secretary | 1996-03-18 | 1999-10-29 |
| GRAVER, Jane Louise | Secretary | 2002-05-01 | 2005-02-09 |
| KANOVSKY, Stephen | Secretary | 2010-09-30 | 2012-09-21 |
| KANOVSKY, Stephen | Secretary | 2010-09-30 | 2012-09-21 |
| LITTLER, William | Secretary | 1999-10-29 | 2002-05-01 |
| MARCHETTI, Charles | Secretary | 2005-02-17 | 2010-09-30 |
| PERELMAN, Michael Roger Sidney | Secretary | 2012-09-21 | 2013-12-19 |
| BUCHALTER, Jeffrey H | Director | 2012-06-01 | 2014-08-05 |
| BUCHALTER, Jeffrey H | Director | 2011-02-01 | 2012-03-26 |
| CLARK, Michael Leslie | Director | 2005-02-17 | 2011-01-31 |
| DAVIS, Stanley Stewart, Professor | Director | 1991-09-01 | 2003-03-31 |
| DE SOUZA, Richard Anthony | Director | 2005-02-17 | 2009-12-03 |
| DEAN, Gordon Douglas | Director | 1991-08-02 | 1992-03-19 |
| DORSEY, Jerry E | Director | 1998-03-31 | 1999-10-29 |
| ELLERS, Steven A | Director | 1998-10-16 | 2005-02-09 |
| FARRAJ, Nidal, Dr | Director | — | 1995-08-01 |
| GAILEY III, John Robert | Director | 1998-03-31 | 1998-10-15 |
| ILLUM, Lisbeth, Professor | Director | — | 1999-08-12 |
| KING, Alan Fernie | Director | 2020-04-22 | 2023-08-01 |
| LITTLE, William G | Director | 1998-10-16 | 2003-03-31 |
| LITTLER, William | Director | 1999-10-29 | 2005-02-09 |
| MARCHETTI, Charles | Director | 2005-02-17 | 2010-09-30 |
| MCLEAN, Andrew Firth | Director | 2014-08-05 | 2020-04-22 |
| MOREL, Donald Eugene | Director | 1994-09-20 | 2005-02-09 |
| MORGAN, Jeremy Lewis | Director | 2023-02-22 | 2025-11-03 |
| MORRA, Bruce, Dr | Director | 2003-05-28 | 2004-12-31 |
| PERELMAN, Michael Roger Sidney | Director | 2010-09-30 | 2013-12-19 |
| REINHART, Charles Augustine | Director | 2011-09-23 | 2014-08-05 |
| ROTHWELL, Nicholas Gordon | Director | 2012-03-26 | 2014-08-05 |
| STRATFORD, Harry Thomas, Dr | Director | 2014-08-05 | 2019-03-31 |
| WATSON, Allan Mark | Director | 2014-08-05 | 2020-04-22 |
| WATTS, Timothy William | Director | 2008-10-01 | 2011-09-22 |
| TRANSATLANTIC CAPITAL BIOSCIENCES LIMITED | Corporate Director | 1992-03-19 | 1994-09-20 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Kyowa Kirin International Plc | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2017-11-30 | Active |
| Archimedes Pharma Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2016-04-06 | Ceased 2017-11-30 |
Filing timeline
Last 20 of 221 total filings
Material constitutional events — rename, articles re-file, resolution
- 2023-12-08 RESOLUTIONS Resolution
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-03-05 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-11-06 | AP01 | officers | Appoint person director company with name date | |
| 2025-11-03 | TM01 | officers | Termination director company with name termination date | |
| 2025-10-07 | AA | accounts | Accounts with accounts type full | |
| 2025-08-22 | CH01 | officers | Change person director company with change date | |
| 2025-03-12 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-10-31 | AA | accounts | Accounts with accounts type full | |
| 2024-02-27 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-02-20 | CH01 | officers | Change person director company with change date | |
| 2024-01-11 | AA | accounts | Accounts with accounts type full | |
| 2023-12-08 | SH19 | capital | Capital statement capital company with date currency figure | |
| 2023-12-08 | RESOLUTIONS | resolution | Resolution | |
| 2023-12-08 | SH20 | capital | Legacy | |
| 2023-12-08 | CAP-SS | insolvency | Legacy | |
| 2023-08-07 | TM01 | officers | Termination director company with name termination date | |
| 2023-05-09 | AP01 | officers | Appoint person director company with name date | |
| 2023-02-28 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-02-02 | CH01 | officers | Change person director company with change date | |
| 2023-02-01 | CH01 | officers | Change person director company with change date | |
| 2023-02-01 | CH01 | officers | Change person director company with change date |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 5
- Capital events
- 0
- Officers appointed
- 1
- Officers resigned
- 1
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.
Year-on-year
FY2023 → FY2024 · period ending 2024-12-31 vs 2023-12-31
-
Turnover
-14%
£300,610,000 £258,656,000
-
Cash
+108.1%
£172,000 £358,000
-
Net assets
+48.6%
£228,058,000 £338,840,000
-
Employees
-18.5%
162 132
-
Operating profit
+348.7%
£28,062,000 £125,916,000
-
Profit before tax
+117.5%
£65,529,000 £142,494,000
-
Wages
+1.8%
£26,551,000 £27,026,000
Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers